Dose finding study of high-dose epirubicin (E) and docetaxel (D) as first-line chemotherapy in advanced breast cancer (ABC)

被引：0
|
作者：
Pagani, O [1 ]
Sessa, C [1 ]
Martinelli, G [1 ]
Crivellari, D [1 ]
Goldhirsch, A [1 ]
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OP37
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] IS THERE A RATIONALE FOR HIGH-DOSE CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED HODGKINS-DISEASE
    HASENCLEVER, D
    SCHMITZ, N
    DIEHL, V
    LEUKEMIA & LYMPHOMA, 1995, 15 : 47 - 49
  • [32] A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
    V J O'Neill
    S B Kaye
    N S Reed
    J Paul
    J A Davis
    P A Vasey
    British Journal of Cancer, 2002, 86 : 1385 - 1390
  • [33] Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer
    Ichinose, Ichiro
    Hamada, Yuzo
    Mitsuyama, Shoshu
    Ishikawa, Emi
    Ikeda, Tadashi
    Kobayashi, Sunao
    Horikoshi, Noboru
    Tamura, Kazuo
    CHEMOTHERAPY, 2008, 54 (05) : 379 - 385
  • [34] High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study
    C Bengala
    R Danesi
    V Guarneri
    I Pazzagli
    S Donati
    C Favre
    S Fogli
    O Biadi
    F Innocenti
    M Del Tacca
    M Mariani
    P F Conte
    Bone Marrow Transplantation, 2003, 31 : 275 - 280
  • [35] Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer
    De Rosa, L
    Lalle, M
    Perillo, A
    Pierelli, L
    Salerno, MG
    Cortesi, E
    Martelli, O
    Pandolfi, A
    Amodeo, R
    Marzetti, L
    Mancuso, S
    Scambia, G
    ANTICANCER RESEARCH, 2001, 21 (2B) : 1367 - 1370
  • [36] A RANDOMIZED COMPARISON OF HIGH-DOSE EPIRUBICIN VERSUS HIGH-DOSE EPIRUBICIN PLUS LONIDAMINE IN ADVANCED BREAST-CANCER PATIENTS - FIRST RESULTS FROM A COOPERATIVE GROUP-STUDY
    DOGLIOTTI, L
    BERRUTI, A
    BUNIVA, T
    ZOLA, P
    BAU, MG
    FARRIS, A
    SAROBBA, MG
    BOTTINI, A
    ALQUATI, P
    DELTETTO, F
    GOSSO, P
    MONZEGLIO, C
    MORO, G
    SUSSIO, M
    PERRONI, D
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 : 747 - 752
  • [37] A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
    Delord, Jean Pierre
    Dalenc, Florence
    Pinguet, Frederic
    Nguyen, Laurent
    Lochon, Isabelle
    Poublanc, Muriel
    Chatelut, Etienne
    Roche, Henri
    ONCOLOGY, 2007, 72 (5-6) : 322 - 325
  • [38] Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
    Sampson, FC
    Beard, SM
    Scott, F
    Vandenberghe, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1015 - 1019
  • [39] High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxeI in metastatic breast cancer: a dose finding study
    Bengala, C
    Danesi, R
    Guarneri, V
    Pazzagli, I
    Donati, S
    Favre, C
    Fogli, S
    Biadi, O
    Innocenti, F
    Del Tacca, M
    Mariani, M
    Conte, PF
    BONE MARROW TRANSPLANTATION, 2003, 31 (04) : 275 - 280
  • [40] Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer
    Lüftner, D
    Wagner, K
    Dingeldein, G
    Haas, A
    Sezer, O
    Mergenthaler, HG
    Wernecke, KD
    Possinger, K
    ANTICANCER RESEARCH, 1999, 19 (4C) : 3583 - 3590
12345